Core recommendations are unchanged — include ECOG PS2 (KPS 60–70) patients by default, consider alternative cohort designs for lower-PS patients, and use additional functional status assessments. The changes below are what shifted between draft and final.
1. Terminology shift: "patients/participants" → "subjects"
Throughout the final version, "patient" and "participant" have been systematically replaced with "subject" (e.g., "trial subjects," "PS2 subjects"). Purely terminological, but relevant if you're aligning protocol language with current FDA usage.
2. Scope narrowed to adults, with a pediatric caveat added
The final guidance adds an explicit statement that recommendations are "specific to inclusion of adult patients in oncology trials," noting PS is sometimes scored differently in pediatric patients (e.g., Lansky scale), while also noting the general principles "may be applicable to pediatric oncology trials." The draft made no such distinction — this is a new scoping clarification.
3. New disadvantage category: "Impact on trial retention"
The final guidance adds an entirely new bullet under Potential Disadvantages that wasn't in the draft: low-PS subjects may rely more on caregivers to attend visits, which can hurt retention and affect required sample size. It explicitly suggests sponsors consider decentralized trial elements to mitigate this, citing FDA's Conducting Clinical Trials with Decentralized Elements (Sept 2024) guidance.
4. Softened language on restricting the efficacy analysis
Draft: "FDA recommends that sponsors consider discussing... a primary efficacy analysis restricted to the participant subset who meet more conventional eligibility criteria."
Final: "sponsors may consider discussing..." — a shift from an FDA recommendation to a more permissive, sponsor-initiated option.
5. Functional status assessments now capped as non-restrictive
The final adds a new sentence to Section IV.C: additional functional assessments (PROs, geriatric assessment, etc.) "should not limit trial eligibility unless there is a scientific and/or clinical rationale for exclusion justified by established safety considerations" — closing a potential loophole where sponsors might use supplemental assessments as a backdoor exclusion criterion.
6. "Wearable devices" → "digital health technologies"
Broader, more future-proof terminology for objective activity monitoring tools.
7. Framing shift on the purpose of broadening eligibility
Draft: broadening criteria "may improve the diversity of clinical trial populations."
Final: broadening criteria "may improve the applicability of clinical trial data to U.S. populations."
This is a notable reframe — diversity-of-population language has been replaced with a data-applicability/generalizability framing.
8. Updated cross-references to companion guidances
The final adds two newly finalized companion guidances to the footnote list: Washout Periods and Concomitant Medications (July 2026) and Laboratory Values (July 2026), and updates the Core Patient-Reported Outcomes in Cancer Clinical Trials guidance citation from a June 2021 draft to an October 2024 (presumably final) version.
The differences are generated by AI models and can contain mistakes. Please double-check the content.